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L ung transplantation is recognized as the best currenttherapy for patients with end-stage pulmonary fail-
ure. The organ shortage for lung transplantation is more
severe than for any other solid organ. Currently, more
than 3200 patients are awaiting lung transplantation in
the United States; in 1998, 486 people died waiting for
a lung transplant.1 Despite the aggressive efforts being
made to increase the donor pool, it is unlikely that
human donors will ever meet the expanding organ
demand. Because mechanical lung replacement devices
have not had a significant clinical impact, animal
donors are being considered as a potential source of
organs. Because there are many limitations to the use of
nonhuman primate donors, currently the pig is being
proposed as the most suitable organ donor for human
xenotransplantation. A major obstacle to successful
Background: Pulmonary xenotransplantation is currently limited by hypera-
cute rejection mediated in part by xenoreactive natural antibody and com-
plement. Transgenic swine organs that express the human complement reg-
ulatory protein CD59 have demonstrated improved survival in models of
pig-to-primate xenotransplantation. 
Objective: The purpose of this study was to evaluate transgenic swine lungs
that express the human complement regulatory protein CD59 in a model of
pig-to-human xenotransplantation. 
Methods: Transgenic swine lungs (n = 5, experimental group) and outbred
swine lungs (n = 6, control group) were perfused with fresh, whole human
blood through a centrifugal pump on an ex vivo circuit. Functional data were
collected throughout perfusion. Immunoglobulin and complement studies
were performed on perfusate samples, and both histologic and immunofluo-
rescent analyses were performed on tissue sections. 
Results: Mean lung survival for the experimental group was increased when
compared with controls, 240 ± 0 minutes versus 35.3 ± 14.5 minutes, respec-
tively, with a P value of less than .01. A decreased rise in pulmonary vascu-
lar resistance at 15 minutes was observed in the experimental group (343 ±
87 mm Hg · L–1 · min–1, in contrast to the control group (1579 ± 722 mm Hg
· L–1 · min–1; P < .01). Pulmonary compliance at 15 minutes was improved
for the experimental group versus control group (9.31 ± 1.41 mL · cm–2 H2O
and 4.11 ± 2.84 mL · cm–2 H2O, respectively; P < .01). SC5b-9 generation in
the plasma perfusate was delayed for the experimental group versus the con-
trol group. Immunofluorescent examination of tissue sections demonstrated
equivalent deposition of immunoglobulin G, immunoglobulin M, C1q, and
C3 in both groups, with reduced deposition of C9 in the experimental group.
Conclusions: Transgenic swine pulmonary xenografts that express the human
complement regulatory protein CD59 demonstrated improved function and
survival in an ex vivo model of pig-to-human xenotransplantation. (J Thorac
Cardiovasc Surg 2000;119:690-9)
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TRANSGENIC SWINE LUNGS EXPRESSING HUMAN CD59 ARE PROTECTED FROM INJURY IN A 
PIG-TO-HUMAN MODEL OF XENOTRANSPLANTATION
pig-to-primate xenotransplantation is hyperacute rejec-
tion.2 Hyperacute rejection results from the binding of
xenoreactive antibodies to donor endothelium with
subsequent activation of complement, which leads to
the loss of endothelial cell integrity, tissue edema,
thrombosis, and loss of graft function.3 Because com-
plement membrane-associated regulatory proteins are
relatively species specific, the transgenic engineering
of swine to express human regulatory proteins is a
potentially viable method of preventing the progression
of hyperacute rejection in swine organs that are
exposed to primate complement.4,5 The complement
regulatory protein CD59 prevents the complete assem-
bly of the membrane attack complex of complement by
blocking the binding of C9 to C5b-8 and inhibiting the
polymerization of C9.5 Expression of human CD59
(hCD59) on the surface of porcine aortic endothelial
cells confers protection against primate complement-
mediated cytotoxicity in vitro, and ex vivo perfusion
with human blood of swine hearts and kidneys trans-
genic for hCD59 demonstrated prolonged survival over
nontransgenic controls.6
Individual organ characteristics define physiologic
mechanisms through which hyperacute rejection and
resulting organ failure may be manifested. Hyperacute
rejection of the lung occurs in a way that makes it
unique compared with other solid organs, such as the
heart or the kidney. In the lung during hyperacute rejec-
tion, there occurs a precipitous rise in pulmonary vas-
cular resistance (PVR), which markedly reduces organ
perfusion and impairs respiratory function. Canine and
porcine lungs that were exposed to human blood for
evaluation as potential extracorporeal oxygenators
revealed a significant reduction in forward pulmonary
perfusive blood flow.7,8 Models of pig-to-human car-
diopulmonary and isolated pulmonary xenotransplanta-
tion have shown that this elevation in PVR is manifest-
ed when hyperacute rejection occurs in these
combinations.9-12 However, one experiment that studied
pig-to-primate lung transplantation in vivo suggested
that the lung was protected from hyperacute rejection.13
Strategies designed to reduce the contribution of
complement to hyperacute rejection in a pig-to-primate
combination have demonstrated the potential for
improved function and survival for pulmonary xeno-
grafts. Transgenic expression of both human decay
accelerating factor (hDAF) and hCD59 in swine lungs
had a protective effect in an ex vivo human plasma per-
fusion model, which was demonstrated by better perfu-
sion and reduced pulmonary edema in the transgenic
organs as compared with unmodified controls.14
Subsequent in vivo pig-to-primate transplantations
with transgenic swine lungs that expressed hCD59 and
hDAF, with or without the administration of cobra
venom factor to the recipient, supported previous
results obtained with the ex vivo plasma perfusion
model; however, these studies did not demonstrate a
protective effect of cobra venom factor alone in this
combination.15 Studies of transgenic lungs that express
hDAF in an ex vivo whole-blood perfusion model of
pig-to-human xenotransplantation demonstrated im-
proved function and survival of organs with high levels
of hDAF expression.16
In the present study, we examined pig-to-primate
lung xenotransplantation in a whole blood perfusion ex
vivo model to identify events associated with rejection
of a discordant pulmonary xenograft and to elucidate
the potential protective effect of the transgenically
expressed isolated hCD59 on a swine lung.
Material and methods
Animals. Outbred Yorkshire swine (Midwest Research
Swine, Gibbon, Minn) that weighed 20 to 30 kg served as
control lung donors. Transgenically engineered swine that
expressed hCD59 (20-30 kg) were supplied by Alexion
Pharmaceuticals Incorporated (New Haven, Conn). They
were derived from founder animals that were generated by
directionally cloning an hCD59 complement DNA into
exon 1 of the murine H2Kb gene4; the purified H2Kb-
hCD59 DNA was then injected into porcine embryos. Use
of the murine major histocompatibility class I gene H2Kb
provided near ubiquitous expression of the hCD59 on most
somatic cells and, most important, on endothelial cell sur-
faces.4 Transgenic swine heterozygous for the hCD59 trans-
gene were screened with the use of slot blot analysis of tail
vein resections as previously described6 before delivery to
our facility. All animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care” for-
mulated by the Institute of Laboratory Animal Resources
and the “Guide for the Care and Use of Laboratory
Animals” formulated by the National Institutes of Health
(NIH Publication No. 86-23, revised 1985).
Donor operation. After the induction of anesthesia with
ketamine (16 mg/kg), tiletamine (Telazol; 4 mg/kg), and
thiopental sodium (Pentothal; 12 mg/kg), the animals were
endotracheally intubated and placed on a mechanical ventila-
tor with inhalational isoflurane (1.5-2 vol%) for maintenance
anesthesia. The animals’ lungs were ventilated with a tidal
volume of 10 cm3/kg and an inspired oxygen concentration of
100%. After a median sternotomy was performed, the peri-
cardium was opened; the inferior vena cava was encircled
twice with umbilical tapes, and the superior vena cava was
encircled inferior to the entrance of the azygous and hemi-
azygos systems. The donor animal was then systemically
heparinized (165 units/kg intravenously), and the inferior
pulmonary ligaments were sharply divided. A euthanizing
dose of thiopental sodium was administered, and the trachea
was clamped at peak inspiration before division of the venae
cavae and procurement of the heart-lung block. The left lung
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Kulick et al 691
692 Kulick et al The Journal of Thoracic and
Cardiovascular Surgery
April 2000
was dissected free from the heart-lung block, and all bronchi
and blood vessels that served other portions of the heart-lung
block were ligated.
Ex vivo lung perfusion model. The lung was instrument-
ed by an endotracheal tube in the left main stem bronchus and
an arterial cannula in the left main pulmonary artery. All
donor lungs were then flushed with up to 500 mL of room
temperature saline solution until the effluent from the pul-
monary veins was clear. An arterial pressure catheter was
placed in line with the pulmonary arterial cannula. The lung
was then placed horizontally in a plastic reservoir. The
venous return drained passively through the pulmonary veins
and was collected in a 3000-mL cardiotomy reservoir
equipped with a 20-µm filter (Medtronic, Anaheim, Calif).
Blood was circulated with a Bio-Medicus centrifugal pump
(Medtronic Bio-Medicus, Eden Prairie, Minn), passed
through a hollow-fiber deoxygenator, and returned to the lung
through the pulmonary artery. A 95% nitrogen/5% carbon
dioxide gas mixture was administered to the deoxygenator
(Medtronic). Perfusate temperature was maintained at 37°C
through the use of a warm water circulator attached to the
deoxygenator. The lung was ventilated with heated, humidi-
fied gas with an inspired oxygen fraction of 50%, delivered
by a ventilator (Siemens 900B; Siemens-Elema, Solna,
Sweden) with physiologic peak end-expiratory pressure
(PEEP), a respiratory rate of 12, and a tidal volume to main-
tain peak airway pressure below 35 cm H2O. Total ischemic
time was consistently less than 20 minutes from the time of
heart-lung block harvest to the time of ex vivo perfusion. All
lung preparations were perfused with fresh human blood that
was obtained from healthy donors and used within 3 hours of
donation. The use of human subjects as blood donors was in
accord with the University of Minnesota Committee on the
Use of Human Subjects in Research. Each perfusion experi-
ment was performed with 1 unit of fresh blood (450 mL) that
was anticoagulated with 2.2 units heparin per milliliter, and
150 mL of crystalloid was added to give an operational total
circuit volume of 600 mL. Normal human blood donor types
used to perfuse the control group included 4 A-positive
donors and 2 O-positive donors. Perfusion of the transgenic
lungs was performed with blood from 3 A-positive donors
and 2 O-positive donors. All blood donors were screened and
selected on the basis of normal levels of xenoreactive natural
antibody, and those who had a level higher than the mean of
the group minus 2 standard deviations were used so that no
organ perfusion study was compromised by low xenoreactive
immunoglobulin (Ig) M or G levels.6
Blood samples were obtained at defined time intervals for
the measurement of antibody, complement, and complete
blood counts including hemoglobin, platelets, and leuko-
cytes. The hemoglobin level of the perfusate was 10 to 12
g/dL at the beginning of each ex vivo perfusion and was con-
sistently above 7 g/dL by the completion of the perfusion.
Perfusion circuits were primed and circulated before perfu-
sion was initiated. Electrolyte and pH adjustments were made
before organ perfusion. Glucose, free water, and electrolytes
were added as needed during the experiment. The end point
for each perfusion experiment was determined by the inabil-
ity to oxygenate the perfusate defined as an arteriovenous
oxygen difference (∆AVO2) less than 10 mm Hg determined
by serial blood gas analyses, the inability to maintain forward
perfusive pulmonary blood flow of 1 mL/gm tissue per
minute at a mean pulmonary perfusion pressure of no greater
than 30 mm Hg, or an increase in the peak airway pressure of
more than 40 mm Hg, with resulting bleb rupture; if none of
these criteria occurred by 240 minutes or more, the experi-
ment was electively terminated.
Functional measurements. In each experiment, pul-
monary artery pressure, pulmonary artery flow, peak airway
pressure, tidal volume, and venous and arterial blood gases
were monitored. From these measurements the PVR, pul-
monary compliance, ∆AVO2, and alveolar-arterial oxygen
gradient (A-a O2 gradient) were calculated. Venous samples
were taken from blood exiting the deoxygenator, and arterial
samples were taken directly from the pulmonary venous
effluent. Blood pH adjustments were made as necessary to
maintain an arterial pH of 7.4. 
PVR was calculated from the measurements of blood flow
with a Bio-Medicus flow probe (Medtronic Bio-Medicus)
and mean pulmonary artery pressure with the use of the fol-
lowing equation:
PVR (mm Hg · L–1 · min–1) = mean pulmonary artery 
pressure (mm Hg)/blood flow (L/min)
Pulmonary compliance was calculated from the measured
tidal volume and peak airway pressure with the use of the fol-
lowing equation:
Pulmonary compliance (mL · cm–2 H2O) = tidal volume (mL)/
peak airway pressure (cm2 H2O) – PEEP (cm2 H2O)
where PEEP is positive end-expiratory pressure.
Change in arteriovenous oxygen (∆AVO2) was calculated
from the formula:
∆AVO2 (mL oxygen/100 mL blood) = PaO2 · 0.0031 +
([1.34 · hemoglobin] · [S
art · 103]) – PvO2 · 0.0031 + 




art is arterial saturation, and Sven is oxygen saturation;
where PaO2 is arterial partial pressure of oxygen, and PvO2 is
venous partial pressure of oxygen in millimeters of mercury
in the venous effluent; and hemoglobin concentration is in
grams per deciliter. 
The A-a O2 gradient was calculated from the formula:
A-a O2 gradient (mm Hg) = ([FIO2 · 713] – PaCO2) – PaO2
Where FIO2 is the fractional inspired oxygen concentration,
PaCO2 is the partial pressure of carbon dioxide in millimeters of
mercury in the venous effluent, and PaO2 is the partial pressure
of oxygen in millimeters of mercury in the venous effluent.
Xenoreactive natural IgG and IgM antibody levels.
Xenoreactive natural IgG and IgM antibody levels were
determined with the use of an enzyme-linked immunosorbent
assay.17 Swine aortic endothelial cells were harvested and
cultured in 96-well plates. Monolayers were fixed with 0.1%
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Kulick et al 693
glutaraldehyde in HBSS-25 mmol/L HEPES, pH 7.4 (Gibco,
Grand Island, NY) and washed. One percent bovine serum
albumin was added to block nonspecific binding sites. Serial
dilutions of human serum samples were added to the wells,
which was followed by sequential washing. Alkaline phos-
phatase-conjugated goat anti-human IgG or IgM was added
to each well, and the plates were incubated for 60 minutes at
37°C for IgG and 4°C for IgM. The reaction was developed
with a solution containing 0.5 mmol/L MgCl2, 1 mg/mL p-
nitrophenylphosphate, and 100 mmol/L diethanolamine, pH
9.5. Well absorbance was determined at 405 nm with a plate
reader (Vmax Kinetic reader; Molecular Devices, Sunnyvale,
Calif). For negative controls, wells were prepared as
described earlier without the addition of human serum.
Statistically significant binding (P < .05) was determined if
absorbance of individual samples was in excess of 2 standard
deviations above the mean binding of negative controls. A
pool of normal human blood donors was used at a 1:2 dilution,
and the absorbance at 405 nm was assigned an arbitrary value
of 100. Absorbance at 405 nm from experimental samples at a
1:2 dilution was compared with this pool and expressed as a
fractional percentage of the pooled value of 100. Total IgG and
IgM levels were measured by nephelometry.
Complement assays. For the fluid phase measurements of
C3a and SC5b-9, blood samples were drawn in ethylenedi-
aminetetraacetic acid tubes at scheduled time points from the
ex vivo perfusion circuit, and the plasma was separated and
frozen immediately at –80°C. C3a as the C3a des-arg product
and SC5b-9 were measured in freshly thawed serum samples
by enzyme-linked immunosorbent assay (Quidel Corp, San
Diego, Calif). Measurement of hemolytic complement activ-
ity of the classic pathway (50% hemolyzing dose of comple-
ment [CH50]) was performed in 96-well flat-bottomed
microtiter plates. Sequential blood samples were collected
from each perfusion experiment and centrifuged for 20 min-
utes at 2000g at 4°C; the serum was pipetted off, aliquoted,
and frozen at –80°C. Serum samples were thawed and serial-
ly diluted with buffer consisting of 5 mmol/L Na Veronal, 145
mmol/L KCl, 0.15 mmol/L CaCl2, and 1 mmol/L MgCl2,
containing 0.5% human serum albumin (Veronal buffer). To
each well in the microtiter plate, 50 µL of diluted serum was
mixed with 50 µL of sensitized sheep red blood cells at
108/mL in Veronal buffer.18 The plates were then incubated at
37°C; mixing occurred after 150 µL of Veronal buffer was
added, for a total of 250 µL per well. Absorbance at 650 nm
was measured with a Vmax kinetic microplate reader.19 CH50
was expressed as the reciprocal of the serum dilution, yield-
ing a 50% reduction in turbidity.
Histology and immunofluorescence. Lung parenchyma
and pulmonary vasculature tissue sections were obtained at
the completion of each experiment. Tissue specimens were
formalin fixed, embedded in paraffin, sectioned, stained with
hematoxylin and eosin, and examined by light microscopy.
Additional tissue samples were embedded in OCT compound
(Sakura Finetek USA Inc, Torrance, Calif) and snap-frozen in
prechilled isopentane and liquid nitrogen and stored at
–80°C. Tissue specimens were sectioned to 4-µm thickness
on a Lipshaw cryostat (Cryotome, Detroit, Mich), air dried,
acetone fixed, and washed with phosphate-buffered saline
solution (pH 7.35-7.45). Fluorescein isothiocyanate (FITC)–
conjugated antibodies were preabsorbed with pig serum for
12 hours to inhibit nonspecific binding, centrifuged for 10
minutes at 10,000g, and separated into aliquots to be stored at
–70°C until needed. The sections were stained with FITC-
conjugated antibodies specific for human IgM, C1q, C3, C4,
properdin, fibrinogen (Diasorin Inc, Stillwater, Minn), and
IgG (Sigma Chemical Company, St Louis, Mo). In addition,
tissues were stained with a murine anti-human monoclonal
antibody specific for C9 neoantigen,20 followed by a fluores-
cein-labeled goat anti-murine monoclonal antibody (Organon
Teknika Corp, Durham, NC). Tissues were also stained with
a murine anti-hCD59 monoclonal antibody (Biodesign
International, Kennebunk, Maine) followed by an FITC-con-
jugated goat anti-murine IgG (Organon Teknika Corp).
Sections were viewed on a Zeiss epifluorescence microscope
(Carl Zeiss, Inc, Thornwood, NY) and photographed.
Statistical analysis. Data are reported as mean ± SD.
Analysis of data was performed using a 2-way analysis of
variance on a commercially available computer statistics
package to determine significance (SPSS Incorporated,
Chicago, Ill).
Results 
Survival time and weight increase of porcine lungs
perfused with human blood. Swine lungs that
expressed hCD59 had prolonged survival versus the con-
trols (240 ± 0 minutes vs 35.3 ± 14.5 minutes, respec-
tively; P < .001). Control lung survival was limited by the
failure of forward perfusate flow and the loss of lung
compliance. All transgenic lungs were functional at the
time of perfusion and were electively terminated (240
minutes). Gross appearance of the control lungs included
petechial hemorrhages on the visceral pleural surface, a
progressive consolidation of the graft with decreased
expiratory recoil, and frothy, blood-tinged endotracheal
tube secretions. The transgenic lungs remained soft and
compliant throughout the perfusion, and the surface of
the lung appeared less ecchymotic when compared with
controls. Comparison of weight gain as a function of
retained perfusate for grafts before and after perfusion
did not reveal a significant difference between control
and transgenic lungs. Control lungs demonstrated a more
rapid and quantitatively higher weight gain than trans-
genics. Baseline weights for controls were 160.3 ± 37 g
and 171.9 ± 25 g for transgenics (t test: P = .57).
Percentage weight gain at the end of perfusion experi-
ments was 78.9% ± 62% for controls and 57% ± 32% for
transgenics (t test: P = .24).
Functional variables. Control lungs demonstrated a
rapid and prolonged rise in PVR in contrast to trans-
694 Kulick et al The Journal of Thoracic and
Cardiovascular Surgery
April 2000
genic lungs (Fig 1). At 30 minutes, PVR was 3558 ±
1902 mm Hg · L–1 · min–1 for controls and 341 ± 89
mm Hg · L–1 · min–1 for transgenics. Pulmonary com-
pliance was improved for transgenic lungs when com-
pared with controls (Fig 1). At 30 minutes, pulmonary
compliance was 4.3 ± 2.9 mL · cm–2 H2O for controls
and 9.2 ± 1.7 mL · cm–2 H2O for transgenics. ∆AVO2
and A-a O2 gradient were similar in both groups (Fig 2). 
Xenoreactive natural antibody levels. All levels
were corrected for dilution with the use of hematocrit
values obtained throughout perfusion with the use of
the following formula: aIg = mIg · (H0 – H1)/H0 where
aIg is the adjusted immunoglobulin level, mIg is the
measured immunoglobulin level, H0 is the hematocrit
at the start of the perfusion, and H1 is the hematocrit at
the point at which a sample was obtained for the mea-
sured immunoglobulin level. Levels were measured at
baseline after circuit prime and at specified times dur-
ing the perfusion experiment. Levels of anti-pig
endothelial cell IgG and IgM antibodies decreased sim-
ilarly in both groups (Fig 3). Before perfusion, xenore-
active IgG levels were 0.78 ± 0.24 units for controls
and 0.82 ± 0.25 units for transgenics. After 30 minutes
of perfusion, there was a 47.6% ± 25.9% reduction in
xenoreactive IgG levels for controls and a 44.3% ±
30.4% reduction for transgenics. Before perfusion,
xenoreactive IgM levels were 1.13 ± 0.12 units for con-
trols and 1.11 ± 0.2 units for transgenics. After 30 min-
utes of perfusion, there was a 41.2% ± 4.7% decrease
in xenoreactive IgM levels for controls and a 44.9% ±
13.9% reduction for transgenics. In contrast to the sig-
nificant decrease in xenoreactive natural antibodies,
Fig 1. PVR and pulmonary compliance for control () and
transgenic (♦) lungs perfused with human blood (mean ±
standard deviation; P = .018 for PVR; P = .001 for pulmonary
compliance transgenic vs control; analysis of variance). Time
0 represents measurements obtained during the first 15 sec-
onds of the experiment. In this and subsequent illustrations, n
= 6 for the control group and n = 5 for the transgenic group. 
Fig 2. ∆AVO2 and A-a O2 gradient for control () and trans-
genic (♦) lungs perfused with human blood (mean ± standard
deviation).
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levels of total IgG and IgM decreased only slightly dur-
ing perfusion in both groups (results not shown).
Hemolytic complement (CH50) activity and com-
plement activation assays. Before perfusion, plasma
CH50 was 75.8 ± 25.2 units for the controls and 75.3 ±
26.2 units for the transgenics. After 30 minutes of per-
fusion, CH50 was reduced by 48.7% ± 8.7% for con-
trols and 36.4% ± 13.9% for transgenics (Fig 4). In all
studies, levels of C3a and SC5b9 increased throughout
the experiment; however, there was delayed elevation
of SC5b9 levels in the perfused transgenic lungs as
compared with controls. C3a levels before perfusion
were 0.958 ± 0.402 ug/mL for controls and 1.026 ±
0.416 ug/mL for transgenics (Fig 5). After 30 minutes
of perfusion, C3a levels were 15.41 ± 3.90 µg/mL for
controls and 14.58 ± 3.78 µg/mL for transgenics.
Fig 3. IgG and IgM xenoreactive natural antibody from con-
trol () and transgenic () lungs perfused with human blood.
Levels are expressed as a percentage of values before perfu-
sion. Data are reported as mean ± standard deviation. 
Fig 4. Plasma levels of total complement hemolytic activity
(CH50) in control () and transgenic () lungs perfused with
human blood. Data are reported as mean ± standard deviation
for percentage decline in CH50 compared with preperfusion
levels.
Fig 5. Plasma levels of complement fragment C3a and solu-
ble complement complex SC5b9 from control () and trans-
genic () lungs perfused with human blood. Data are report-
ed as mean ± standard deviation (**P < .01, t test).
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SC5b9 levels before perfusion were 136 ± 181 ng/mL
for controls and 248 ± 219 ng/mL for transgenics. After
30 minutes of perfusion, SC5b9 levels were 4069 ±
1851 ng/mL for controls and 901 ± 501 ng/mL for
transgenics (t test: P < .01).
Histopathology and immunofluorescence. Tissues
from the control group obtained after perfusion
showed characteristic changes consistent with hypera-
cute rejection, including interstitial and alveolar septal
edema, neutrophil infiltration, and some detachment
Fig 6. Histologic features of pulmonary parenchymal sections obtained after the completion of the perfusion
experiments with human blood (Hematoxylin and eosin stain; original magnification, ×40). Control porcine lung
tissues reveal interstitial, perivascular, peribronchial hemorrhage, and neutrophil infiltration. Transgenic porcine
lung tissues demonstrate reduced interstitial hemorrhage, interalveolar septal edema and congestion, and pre-
served pulmonary tissue architecture.
Fig 7. Immunofluorescence analysis of porcine lungs perfused with human blood reveals equivalent deposition
of C3 for both control and transgenic lungs. Terminal complement component C9 deposition was reduced in
transgenic lungs as compared with control lungs. Preperfusion right porcine lung specimens revealed strong
expression of hCD59 in transgenic lung parenchyma and no hCD59 reactivity in control lung parenchyma.
of endothelial cells from the basement membrane (Fig
6); other findings included microvascular thrombosis
and scattered areas of intra-alveolar hemorrhage (data
not shown). In contrast, tissues from the transgenic
group demonstrated reduced injury. There were inter-
stitial edema, alveolar septal congestion, and neu-
trophil infiltration, but the endothelial cell layers were
preserved in both arterioles and venules (Fig 6).
Tissues from all perfusion experiments were studied
for the presence of immunoglobulin and complement
deposition. Specimens obtained after completion of
perfusion from both groups demonstrated similar
degrees of deposition of IgG, IgM, C1q, C3, C4, and
fibrinogen, as illustrated in Fig 7 for C3. In lungs from
the transgenic group, however, there was marked inhi-
bition of C9 deposition (Fig 7). There was minimal to
no deposition of properdin in all specimens from both
the control and transgenic groups (data not shown).
Tissue samples obtained from the right unperfused
lung of the donor swine demonstrated intense staining
for hCD59 in the transgenic lung tissues but no stain-
ing of hCD59 in the controls (Fig 7).
Discussion 
In the pig-to-primate combination, natural antibod-
ies and complement are known to mediate hyperacute
rejection of a cardiac or renal xenograft.21 Similar
mechanisms have been proposed to explain the imme-
diate rejection of a pig lung transplanted into pri-
mates.15,24 Both in vivo and ex vivo studies consis-
tently demonstrated a rapid loss of graft function
characterized by an increase in PVR, loss of pul-
monary compliance, and, over time, an impairment of
the oxygenating capabilities of the graft.9-16,22,23 In
the studies reported here, we used an ex vivo model of
pig-to-human lung transplantation and analyzed the
injury inflicted by human blood on lungs from normal
pigs in comparison with lungs from transgenic donors
that express hCD59. We found that perfusion of nor-
mal lungs caused a rapid loss of function after a
marked increase in PVR and a decrease of lung com-
pliance, similar to previous studies.7,8 However, in
contrast with previous observations, we detected no
reduction in ∆AVO2, even at the time of organ func-
tion loss, and a relatively low degree of edema forma-
tion. Several factors may have contributed to maintain
these parameters in the face of severely increasing
PVR and diminishing compliance. First, in our exper-
iments, we limited the mean pulmonary perfusion
pressure to 30 mm Hg;  early in the development of
the model we observed that with higher pressures, up
to 60 mm Hg, there was rapid loss of the oxygenating
capacity and sequestration of the perfusate within the
graft. By reducing the mechanical hemodynamic
injury, loss of the ability to perfuse the graft because
of the rise in PVR became the limiting factor for graft
survival. Second, the use of blood as the perfusate
fluid instead of plasma assured improved oxygena-
tion; this may have prevented endothelial cell hypox-
ia followed by intercellular gap formation and
edema14 and the consequent loss of oxygenation.
Third, we limited the amount of crystalloid solution
added to the blood to avoid reducing the colloid-
osmotic pressure of the perfusion fluid to levels that
may promote alveolar transudation and pulmonary
edema.
Perfusion of normal lungs and hCD59 lungs with
human blood was associated with tissue deposition of
IgM, IgG, and complement components C1, C3, and
C4, marked reduction in anti-pig antibodies and total
complement activity from the plasma perfusate, and
generation of complement activation products C3a and
SC5b-9. However, in comparison to normal lungs,
hCD59 lungs had reduced deposition of C9 and less
histologic evidence of tissue damage. Histologic find-
ings in normal lungs consisted of endothelial cell dam-
age, microvascular thrombosis, intra-alveolar hemor-
rhage, edema, and neutrophil infiltration, resulting in
the rapid dysfunction of the lung. These findings sup-
port the concept that the pathophysiologic features of
the immunologic injury but not physiologic responses
induced by human blood on a pig lung are analogous to
that described earlier with a pig heart or kidney with a
similar perfusion model.6 In these cases, the organ
damage is representative of the process of hyperacute
rejection that a porcine organ undergoes when trans-
planted into a primate.15,24,25 In one study in which a
pig lung was transplanted orthotopically into baboons
and cynomolgus monkeys, with the contralateral lung
left in place, there was little or no deposition of
immunoglobulins and complement in the graft,13 a
result that may have been due to inadequate perfusion,
given the rise in PVR in the xenograft with probable
shunting of pulmonary blood flow to the native lung. 
Our studies demonstrated that lungs that express
hCD59 are strongly protected from injury induced by
perfusion with human blood. These lungs survived for
at least the 4 hours of observation, in marked contrast
to control lungs that survived only an average of 35
minutes. The prolonged survival of hCD59 lungs was
associated with decreased PVR and maintenance of
pulmonary compliance until termination of the experi-
ment. The differences observed between the transgenic
organs and those of outbred controls could potentially
be attributed to differences in housing and swine genet-
ics, although less likely than by way of the expression
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of the hCD59 transgene. The pulmonary arterial flows
demonstrated are reduced from porcine physiologic
levels and may not support adequate cardiac output in
an in vivo model of porcine-to-primate pulmonary
xenotransplantation. However, this significant protec-
tion provided by hCD59 against hyperacute injury of a
pig lung by human blood is comparable to the
improved function observed with perfused lungs that
expressed hDAF16 or hDAF plus hCD59.14
Although these experiments do not allow quantitation
of the degree of protection, our results highlight the
very important role played by the completely assem-
bled membrane attack complex (ie, containing incorpo-
rated C9) in the pathogenesis of hyperacute rejection in
this pig lung–to-human model system. Although addi-
tional products of complement activation such as C3a
and C5a may also be important, our results suggest the
predominant role of the membrane attack complex in
hyperacute xenogeneic lung injury.
Whereas the plasma perfusate of both normal and
hCD59 lungs showed strong complement activation
when assessed by generation of C3a, in the current
series of experiments with whole blood, formation of
the soluble complex SC5b-9 was markedly retarded
with the hCD59 lungs. In contrast to results with nor-
mal lungs, SC5b-9 levels with hCD59 lungs were only
slightly elevated after 30 minutes of perfusion but were
greatly increased after 4 hours of perfusion. The slow-
er formation of SC5b-9 in the transgenic group is like-
ly due to several factors. The early rise of SC5b-9 lev-
els with normal lungs may be, to a large extent, due to
dissociation into the fluid phase of tissue-bound mem-
brane attack complexes that had rapidly bound in the
normal lungs but not to the hCD59 lungs. In addition,
reduced tissue inflammation in the hCD59 lungs may
prevent amplification of C5 activation as might occur in
the control lungs because of activation by other media-
tors of inflammation. The more rapid blood flow in the
hCD59 lungs may impair the fluid phase interaction
among late-acting complement proteins, either directly
or through the action of complement regulatory pro-
teins. 
In conclusion, our studies demonstrate that a porcine
lung that expresses hCD59, in comparison to normal
controls, undergoes reduced tissue injury when per-
fused with human blood. The hCD59 lungs had
improved function and survival, with diminished tissue
deposition of C9 and delayed generation of SC5b-9 in
the plasma perfusate. These studies suggest that in pig-
to-human models of xenotransplantation, hyperacute
tissue injury is mediated to a major extent by the
assembly of the complete membrane attack complex of
complement, C5b-9.
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Discussion
Dr Thomas K. Waddell (Toronto, Ontario, Canada). You
showed an 8-fold increase in the perfusion time. Having done
a bit of work with ex vivo perfusion, I know that you cannot
perfuse these models forever. Even perfusing with autologous
blood, you are going to damage the lung because of, in some
cases, complement activation. Have you studied a control
group with autologous perfusion, either as part of this series
or in previous experiments? 
Dr Kulick. Yes, we did look at autologous perfusion with
pig lungs with their own blood. We found that, after 4 to 6
hours of perfusion, oxygenation would decrease, pulmonary
edema would form, and this limited the validity of this model
for hyperacute rejection studies only. 
Dr Valerie W. Rusch (New York, NY). Tell us where you
are going next. 
Dr Kulick. The CD59 transgenic has been improved on.
There are double transgenics now for both decay-accelerating
factor and hCD59. At our institution, we now have access to
transgenic swine that are double transgenic for the h-trans-
ferase gene, which downregulates endogenous expression of
the α-gal epitope in addition to hCD59, and we hope to start
some studies with those double transgenic organs soon.
Dr Mark K. Ferguson (Chicago, Ill). Is there some
variability in the expression of hCD59 in these transgenic
animals? 
Dr Kulick. Interestingly, there is. All of the animals that
we used were heterozygous. Homozygous expression of the
hCD59 transgene has not been shown to increase the tissue
expression of hCD59. We obtained one animal that was an
hCD59 low expresser. We tested the lungs on our perfusion
circuit, and it behaved much as a control lung did. This was
not included in our results presented today. 
Dr Ferguson. At the conclusion of the 4-hour perfusion
period, what does the lung look like? 
Dr Kulick. The lung does not look like a healthy lung, but
it does not look that bad. The control lungs are firm and con-
solidated to the touch, and they have confluent hemorrhagic
petechiae on their surface. The transgenic lungs have scat-
tered areas of petechial hemorrhage, but they are soft. Their
ability to oxygenate is good, but the flows may not be suffi-
cient to support transplantation into an in vivo primate model. 
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